A 6-Week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 1915-1923

  Maul, Eugenio ^a   Carrasco, Félix Gil ^b   Costa, Vital Paulino ^c   Casiraghi, Javier F ^d   Vargas, Enrique ^e   Sarmina, Judith S ^f   Mayol, Renato ^g  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Asociacion para Evitar la Ceguera en Mexico IAP   (Mexico)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^e Instituto Nacional de Oftalmología "Dr Francisco Contreras Campos"   (Peru)

^f HOSPITAL REGIONAL LIC ADOLFO LÓPEZ MATEOS   (Mexico)

^g Alcon Research Ltd   (Brazil)

Author keywords

glaucoma; latanoprost; ocular hypertension; prostaglandin; travoprost

Indexed keywords

LATANOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; BLURRED VISION; CENTRAL AMERICA; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISCOMFORT; EYE PAIN; FEMALE; FEVER; HUMAN; HYPERPIGMENTATION; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OPEN STUDY; PARALLEL DESIGN; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOUTH AMERICA; TREATMENT DURATION; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 36749004341     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.006     Document Type: Article

References (31)

1. Quigley H., and Broman A. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90 (2006) 262-267
2. Kass M., Heuer D., Higginbotham E., et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 120 (2002) 701-713 discussion 829-830
3. Heijl A., Leske M., Bengtsson B., et al., for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results From the Early Manifest Glaucoma Trial. Arch Ophthalmol 120 (2002) 1268-1279
4. Marquis R., and Whitson J. Management of glaucoma: Focus on pharmacological therapy. Drugs Aging 22 (2005) 1-21
5. Ishida N., Odani-Kawabata N., Shimazaki A., and Hara H. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 24 (2006) 1-10
6. Gaskin B., Carroll S., Gamble G., et al. Glaucoma management trends in Australia and New Zealand. Clin Experiment Ophthalmol 34 (2006) 208-212
7. Lee D., and Higginbotham E. Glaucoma and its treatment: A review. Am J Health Syst Pharm 62 (2005) 691-699
8. Netland P., Landry T., Sullivan E., et al., for the Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132 (2001) 472-484
9. Camras C., and for the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. Ophthalmology 103 (1996) 138-147
10. Sherwood M., Brandt J., and for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 45 Suppl 4 (2001) S361-S368
11. Fechtner R., Khouri A., Zimmerman T., et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 126 (1998) 37-41
12. Warwar R., Bullock J., and Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 105 (1998) 263-268
13. Miyake K., Ota I., Ibaraki N., et al. Enhanced disruption of the bloodaqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol 119 (2001) 387-394
14. Travatan (travoprost) [package insert] (2004), Alcon Laboratories, Inc, Fort Worth, Tex
15. Xalatan (latanoprost) [package insert] (2006), Pfizer Inc, New York, NY
16. Reardon G., Schwartz G., and Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. EurJ Ophthalmol 13 Suppl 4 (2003) S44-S52
17. Parrish R., Palmberg P., Sheu W., and for the XLT Study Group. A comparison oflatanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135 (2003) 688-703
18. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Available at:
19. http://www.wma.net/e/policy/b3.htm
20. European Agency For the Evaluation of Medicinal Products, International Conference on I-larmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002. Available at:
21. http://www.http://www.emea.eu.int
22. Zar J. Biostatistical Analysis. 2nd ed (1984), Prentice Hall, Inc, Englewood Cliffs, NJ
23. Goldberg I., Cunha-Vaz J., Jakobsen J., et al., for the International Travoprost Study Group. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 10 (2001) 414-422
24. Galloway G., Eke T., and Broadway D. Periocular cutaneous pigmentary changes associated with bimatoprost use. Arch Ophthalmol 123 (2005) 1609-1610
25. Orzalesi N., Rossetti L., Bottoli A., and Fogagnolo P. Comparison of the efFects oflatanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113 (2006) 239-246
26. Dubiner H., Sircy M., Landry T., et al. Comparison of the diurnal ocular hypotensive effect oftravoprost and tatanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 26 (2004) 84-91
27. Chew P., Rogana Pongpun P., Euswas A., et al. Intraocular pressure lowering effect and safety of travoprost 0.004% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Glaucoma 8 (2006) 13-19
28. Sharif N., Kelly C., Crider J., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19 (2003) 501-515
29. Ota T., Aihara M., Narumiya S., and Araie M. The effects of prostaglandin analogues on lOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 46 (2005) 4159-4163
30. Law S., Song B., Fang E., and Caprioli J. Feasibility and efficacy of a mass switch From latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology 112 (2005) 2123-2130
31. Bournias T., Lee D., Gross R., and Mattox C. Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension [published correction appears in J Ocul Pharmacol Ther. 2004;20:183].J Ocul Pharmacol Ther 19 (2003) 193-203